Unnatural Products has secured $45 million in Series B financing to propel its development of macrocyclic peptide therapeutics, following a significant collaboration with Novartis potentially worth $1.7 billion. This Santa Cruz-based biotech aims to tackle chronic diseases by targeting key intracellular protein interactions that traditional drug modalities struggle to address, particularly in cardiometabolic, inflammatory, and neurodegenerative conditions.

The importance of this development lies in the unique properties of macrocyclic peptides, which bridge the gap between small molecules and biologics. Their ability to selectively bind to complex intracellular targets may unlock new therapeutic avenues for diseases previously deemed “undruggable.” With an integrated discovery platform that combines computational design and high-throughput testing, Unnatural Products is poised to advance multiple lead programs toward clinical development, potentially transforming treatment strategies for chronic and age-related diseases.

For professionals in the longevity field, this represents a promising shift in therapeutic modalities. I highly recommend exploring the full article to understand the implications of Unnatural Products’ innovative approach and its potential impact on the future of drug development.

Source: longevity.technology